Identification of YES1 Inhibitors From Approved Drugs Using a Multimodal Deep Learning Framework
Molecular Informatics · 2026
DOI: 10.1002/minf.70061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Informatics, 2026. Verfasst von Takayoshi Kawabata und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-yes, Deep Learning, Drug Repositioning, Antineoplastic Agents. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
While anti‐human epidermal growth factor receptor 2 (HER2) drugs, including trastuzumab improve the prognosis of patients with HER2‐positive cancers, acquired resistance by cancer cells remains a significant clinical challenge. We had previously reported that YES1 is overexpressed in trastuzumab‐resistant breast and lung cancer cells, and that its inhibition restores trastuzumab sensitivity. However, no approved drug specifically targets YES1. In this study, as a drug repositioning approach aimed at rapid clinical application, we constructed a machine learning model capable of learning the interactions between compounds and target proteins and conducted a screening of approved drugs. The strategy identified chlorpromazine and raloxifene as hit compounds. In vitro validation demonstrated that they effectively inhibited YES1 activation at 15 μM after 48 h. The findings suggested that the identified approved drugs might represent promising therapeutic options for overcoming anti‐HER2 drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Pharmacy, Okayama University Hospital, Okayama, Japan.
- Center for Education in Medicine and Health Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Pharmaceutical Sciences for Health Crisis Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.
- Department of Pharmacy, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
- Digital Innovation Section, Digital Transformation Promotion Department, Nippon Shinyaku co., Ltd., Kyoto, Japan.
ORCID-Profile: Tatsuaki Takeda, Yuta Tanaka, Soichiro Ushio, Tomonori Sakai, Takashi Makita, Shinichi Toyooka, Yoshito Zamami
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kawabata, T., Takeda, T., Tanaka, Y., Ushio, S., Miyamoto, A., Nakagomi, K., Sakai, T., Maruyama, R., Makita, T., Hamano, H., Toyooka, S., & Zamami, Y. (2026). Identification of YES1 Inhibitors From Approved Drugs Using a Multimodal Deep Learning Framework. Molecular Informatics. https://doi.org/10.1002/minf.70061
Vancouver
Kawabata T, Takeda T, Tanaka Y, Ushio S, Miyamoto A, Nakagomi K, et al. Identification of YES1 Inhibitors From Approved Drugs Using a Multimodal Deep Learning Framework. Molecular Informatics. 2026. doi:10.1002/minf.70061
BibTeX
@article{Kawabata2026,
author = {Kawabata, Takayoshi and Takeda, Tatsuaki and Tanaka, Yuta and Ushio, Soichiro and Miyamoto, Akira and Nakagomi, Koki and Sakai, Tomonori and Maruyama, Risa and Makita, Takashi and Hamano, Hirofumi and Toyooka, Shinichi and Zamami, Yoshito},
title = {Identification of YES1 Inhibitors From Approved Drugs Using a Multimodal Deep Learning Framework},
journal = {Molecular Informatics},
year = {2026},
doi = {10.1002/minf.70061}
}
EUVIMED